Evidence map›Paper›PMID 40681261›Full record

ArticleJACC. Case reports2025

Multimodal Imaging Evaluation of Myocardial Involvement in Rare Oculoleptomeningeal Hereditary Transthyretin Amyloidosis.

Moritz J Hundertmark, Martin Zinkernagel, Tatiana Brémova-Ertl, Pascal Escher, Anina Bauer, Federico Caobelli, Yara Banz, Andreas Flammer, Michele V Martinelli, Christoph Gräni

Abstract readCase Reports
In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Moritz J HundertmarkDepartment of Cardiology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Electronic address: https://twitter.com/MJHundertmark.
Martin ZinkernagelDepartment of Ophthalmology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Tatiana Brémova-ErtlDepartment of Neurology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Pascal EscherDepartment of Ophthalmology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Anina BauerDepartment of Human Genetics, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Federico CaobelliDepartment of Nuclear Medicine, University Hospital of Bern, University of Bern, Bern, Switzerland.
Yara BanzInstitute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
Andreas FlammerDepartment of Cardiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Michele V MartinelliDepartment of Cardiology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland.
Christoph GräniDepartment of Cardiology, Inselspital, University Hospital of Bern, University of Bern, Bern, Switzerland. Electronic address: christoph.graeni@insel.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn hereditary (variant) transthyretin amyloidosis (vATTR), cardiomyopathy leads to worse outcomes. Of 140 identified TTR gene mutations, few are associated with oculoleptomeningeal amyloidosis. It remains unclear whether these mutations are linked to a cardiac phenotype. CASE SUMMARY: A 59-year-old man from Bosnia and Herzegovina initially presented with transient vision loss and was ultimately diagnosed with rare p.Ile127Met vATTR. We describe a detailed investigation of myocardial involvement harnessing multimodal cardiovascular imaging. DISCUSSION: No previous reports have specifically addressed the cardiac phenotype of oculoleptomeningeal amyloidosis. Our paper depicts a mild cardiac phenotype for the p.Ile127Met variant highlighting the need for awareness among cardiologists and emphasizing the necessity for close patient monitoring and expertise in evolving disease-modifying treatments. TAKE-HOME MESSAGES: Early diagnosis and risk stratification in patients with vATTR are challenging. Cardiologists need an increased awareness because they may encounter patients with seemingly rare vATTR, such as the p.Ile127Met variant discussed here.

Indexed as

amyloidosisCM-ATTRp.Ile127Metrare diseasevATTR

Identifiers

PMID40681261
PMCPMC12441426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.